कंपनी का अवलोकन
IO Biotech, Inc. operates as a clinical-stage biopharmaceutical entity focused on the development of immune-modulating therapeutic cancer vaccines, utilizing its proprietary T-win technology platform to target cancer cells and immune-suppressive cells. The company functions within the healthcare sector and specifically the biotechnology industry, an area characterized by high research and development costs and a reliance on future regulatory approvals for commercial viability. Its current market capitalization stands at $3.45M, while its annual revenue is not available for the trailing twelve months, and it employs a workforce of 80 individuals. These valuation and operational metrics indicate that the company is a small-cap entity with a limited financial footprint relative to large pharmaceutical peers, suggesting a high-risk profile typical of early-stage biotechnology firms that have not yet achieved significant commercial revenue streams to offset substantial development expenditures.
वित्तीय स्वास्थ्य
The company reports a net income loss of $-88,349,000 for the trailing twelve months, while revenue figures are unavailable, and EBITDA stands at $-91,802,000. The significant negative net income relative to the unavailable revenue data reveals a cost structure dominated by heavy research and development expenses that currently exceed any generated sales, a common dynamic for clinical-stage companies before product launch. Free cash flow is reported at $-49,063,376, which indicates a lack of financial flexibility as the company must rely on external capital sources to fund its ongoing operations and development pipeline. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet generated profitable operations or revenue sufficient to calculate meaningful percentage margins. On the liability side, the company holds $30.66M in cash against $18.12M in debt, resulting in a debt-to-equity ratio of 1988.91, which suggests an extremely leveraged balance sheet structure relative to equity. Despite the high debt-to-equity figure, the current ratio is 2.01, indicating that the company possesses sufficient current assets to cover its short-term liabilities and maintain liquidity in the near term. Return on equity is -240.5% and return on assets is -88.6%, metrics that reveal that management has not yet achieved positive returns on the capital invested by shareholders or utilized in asset deployment.
मूल्यांकन आकलन
The trailing P/E ratio is unavailable, while the forward P/E is listed as -0.13, a metric that implies the market does not expect near-term positive earnings growth or that the company is currently unprofitable. The price-to-book ratio is 3.69, indicating that the market values the company at a significant premium over its net asset book value, which often occurs when investors anticipate future catalysts or intellectual property value that is not yet reflected in current balance sheet assets. The price-to-sales ratio is unavailable, and the EV/EBITDA stands at 0.13, suggesting an enterprise valuation that is extremely low relative to its negative earnings, a valuation characteristic often found in distressed or pre-revenue biotechnology companies. The stock has traded between a 52-week high of $2.79 and a 52-week low of $0.03, placing the current trading price in a range that reflects extreme volatility and a significant distance from the recent yearly peak. The beta value is 0.89, which indicates that the stock's price volatility is slightly lower than the broader market average, suggesting that while the stock moves with the market, it does not exhibit the extreme swings typical of small-cap biotechnology equities.
Growth & Income
Revenue growth year-over-year is unavailable, and earnings growth year-over-year is also unavailable, preventing a direct comparison of whether earnings are growing faster or slower than revenue due to the absence of historical baseline data. Since the company does not pay dividends, the dividend yield is unavailable and the payout ratio is 0.0%, meaning the company reinvests all available capital and retained earnings back into its research, development, and operational activities rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage firms that prioritize advancing their T-win technology platform and candidate IO102-IO103 over providing immediate income returns to investors. The overall growth and income profile is defined by a complete absence of current profitability, dividend distributions, or historical growth data, leaving the company's future trajectory entirely dependent on the successful clinical progression of its therapeutic candidates.